Ruxolitinib improved hematocrit and white blood cell levels in PV patients, showing superiority over hydroxyurea and reducing phlebotomy frequency. In cGVHD patients, ruxolitinib reduced ...

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. Incyte Corporation is among the best ...

Incyte (Nasdaq:INCY) today announced final 24-week data from the Phase 3 TRuE-AD4 study evaluating the efficacy and safety of ...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura ® (ruxolitinib) cream 1.5% to ...

Indications span MF and PV in adults, plus acute/chronic GVHD in patients ≥12 years, positioning XR as a once-daily ...

FDA cleared once-daily ruxolitinib XR for MF, HU-refractory/intolerant PV, and steroid-refractory acute/chronic GVHD after ...

Ruxolitinib improves hematocrit control and treatment response in polycythemia vera compared to best available therapy. Patients on ruxolitinib show better Myeloproliferative Neoplasms-Symptom ...

Please provide your email address to receive an email when new articles are posted on . Ruxolitinib-treated patients achieved greater differences from baseline in itch intensity vs. vehicle. More ...

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) ...

Jak1/2 inhibitor ruxolitinib is a promising agent for treating steroid-refractory GvHD after allogeneic hematopoietic stem cell transplantation (SCT) to produce quick and durable responses. However, ...

Patients were randomized to receive either ruxolitinib 5mg twice daily (BID) plus standard of care (SoC), ruxolitinib 15mg BID plus SoC or placebo plus SoC. A Phase 3 trial of ruxolitinib did not meet ...